USA, Pervasis Therapeutics Closes $17M Financing

Pervasis Therapeutics, a clinical stage company developing a broad portfolio of biologically active therapeutics, completed the initial closing of a $17m third round of financing.
Participants in the investment included previous investors Flagship Venture Partners, Polaris Venture Partners and Highland Capital Partners, and new investor, the Richter Family Fund.
According to a statement, the funds will be used to support the Cambridge, MA.-based company’s ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease and potentially other conditions, and to advance its lead program, Vascugel, which is being developed to prevent arteriovenous access failure in hemodialysis patients.

Join the discussion